Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Disease relapse is the major cause of treatment failure after allogeneic stem cell transplantation (allo-SCT) in acute myeloid leukemia (AML). To identify AML-associated genes prognostic of AML relapse post–allo-SCT, we resequenced 35 genes in 113 adults at diagnosis, 49 of whom relapsed. Two hundre...
| Váldodahkkit: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Journal article |
| Giella: | English |
| Almmustuhtton: |
American Society of Hematology
2016
|
| _version_ | 1826275025356849152 |
|---|---|
| author | Quek, L Ferguson, P Metzner, M Ahmed, I Kennedy, A Garnett, C Jeffries, S Walter, C Piechocki, K Timbs, A Danby, R Raghavan, M Peniket, A Griffiths, M Bacon, A Ward, J Wheatley, K Vyas, P Craddock, C |
| author_facet | Quek, L Ferguson, P Metzner, M Ahmed, I Kennedy, A Garnett, C Jeffries, S Walter, C Piechocki, K Timbs, A Danby, R Raghavan, M Peniket, A Griffiths, M Bacon, A Ward, J Wheatley, K Vyas, P Craddock, C |
| author_sort | Quek, L |
| collection | OXFORD |
| description | Disease relapse is the major cause of treatment failure after allogeneic stem cell transplantation (allo-SCT) in acute myeloid leukemia (AML). To identify AML-associated genes prognostic of AML relapse post–allo-SCT, we resequenced 35 genes in 113 adults at diagnosis, 49 of whom relapsed. Two hundred sixty-two mutations were detected in 102/113 (90%) patients. An increased risk of relapse was observed in patients with mutations in WT1 (P = .018), DNMT3A (P = .045), FLT3 ITD (P = .071), and TP53 (P = .06), whereas mutations in IDH1 were associated with a reduced risk of disease relapse (P = .018). In 29 patients, we additionally compared mutational profiles in bone marrow at diagnosis and relapse to study changes in clonal structure at relapse. In 13/29 patients, mutational profiles altered at relapse. In 9 patients, mutations present at relapse were not detected at diagnosis. In 15 patients, additional available pre–allo-SCT samples demonstrated that mutations identified posttransplant but not at diagnosis were detectable immediately prior to transplant in 2 of 15 patients. Taken together, these observations, if confirmed in larger studies, have the potential to inform the design of novel strategies to reduce posttransplant relapse highlighting the potential importance of post–allo-SCT interventions with a broad antitumor specificity in contrast to targeted therapies based on mutational profile at diagnosis. |
| first_indexed | 2024-03-06T22:52:25Z |
| format | Journal article |
| id | oxford-uuid:5f3c3ec6-1b7e-4b4c-9e53-8c2b4b90ce60 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:52:25Z |
| publishDate | 2016 |
| publisher | American Society of Hematology |
| record_format | dspace |
| spelling | oxford-uuid:5f3c3ec6-1b7e-4b4c-9e53-8c2b4b90ce602022-03-26T17:46:01ZMutational analysis of disease relapse in patients allografted for acute myeloid leukemiaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5f3c3ec6-1b7e-4b4c-9e53-8c2b4b90ce60EnglishSymplectic Elements at OxfordAmerican Society of Hematology2016Quek, LFerguson, PMetzner, MAhmed, IKennedy, AGarnett, CJeffries, SWalter, CPiechocki, KTimbs, ADanby, RRaghavan, MPeniket, AGriffiths, MBacon, AWard, JWheatley, KVyas, PCraddock, CDisease relapse is the major cause of treatment failure after allogeneic stem cell transplantation (allo-SCT) in acute myeloid leukemia (AML). To identify AML-associated genes prognostic of AML relapse post–allo-SCT, we resequenced 35 genes in 113 adults at diagnosis, 49 of whom relapsed. Two hundred sixty-two mutations were detected in 102/113 (90%) patients. An increased risk of relapse was observed in patients with mutations in WT1 (P = .018), DNMT3A (P = .045), FLT3 ITD (P = .071), and TP53 (P = .06), whereas mutations in IDH1 were associated with a reduced risk of disease relapse (P = .018). In 29 patients, we additionally compared mutational profiles in bone marrow at diagnosis and relapse to study changes in clonal structure at relapse. In 13/29 patients, mutational profiles altered at relapse. In 9 patients, mutations present at relapse were not detected at diagnosis. In 15 patients, additional available pre–allo-SCT samples demonstrated that mutations identified posttransplant but not at diagnosis were detectable immediately prior to transplant in 2 of 15 patients. Taken together, these observations, if confirmed in larger studies, have the potential to inform the design of novel strategies to reduce posttransplant relapse highlighting the potential importance of post–allo-SCT interventions with a broad antitumor specificity in contrast to targeted therapies based on mutational profile at diagnosis. |
| spellingShingle | Quek, L Ferguson, P Metzner, M Ahmed, I Kennedy, A Garnett, C Jeffries, S Walter, C Piechocki, K Timbs, A Danby, R Raghavan, M Peniket, A Griffiths, M Bacon, A Ward, J Wheatley, K Vyas, P Craddock, C Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia |
| title | Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia |
| title_full | Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia |
| title_fullStr | Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia |
| title_full_unstemmed | Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia |
| title_short | Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia |
| title_sort | mutational analysis of disease relapse in patients allografted for acute myeloid leukemia |
| work_keys_str_mv | AT quekl mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT fergusonp mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT metznerm mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT ahmedi mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT kennedya mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT garnettc mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT jeffriess mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT walterc mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT piechockik mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT timbsa mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT danbyr mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT raghavanm mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT peniketa mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT griffithsm mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT bacona mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT wardj mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT wheatleyk mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT vyasp mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia AT craddockc mutationalanalysisofdiseaserelapseinpatientsallograftedforacutemyeloidleukemia |